Directory
Plain-language profiles of peptides, GLP-1 medications, hormones, and longevity-adjacent treatments. Each shows regulatory status, evidence level, and sources.
11 treatments
A synthetic 15-amino-acid peptide marketed for tissue healing and recovery. It is not FDA-approved for any use, and human clinical evidence is essentially absent.
Semaglutide prepared by compounding pharmacies rather than the FDA-approved manufacturer. The molecule may be the same, but these specific products are not FDA-reviewed or approved.
A once-weekly injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes and to reduce cardiovascular events in adults with diabetes.
A once-daily injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda), including in adolescents 12 and older.
A long-established oral medication FDA-approved for type 2 diabetes. It is studied off-label for aging-related outcomes but is not FDA-approved for longevity.
NAD+ is a coenzyme central to metabolism; NMN and NR are precursors sold as supplements to raise NAD+ for longevity and energy claims. They are not FDA-approved drugs.
An mTOR-inhibiting drug FDA-approved to prevent kidney transplant rejection and to treat LAM. It attracts off-label longevity interest from animal studies but is not FDA-approved for aging.
A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management and cardiovascular risk reduction (Wegovy).
A growth-hormone-releasing factor analog and the only FDA-approved medication to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Prescription testosterone (injections, gels, patches, pellets) FDA-approved to treat hypogonadism in males from identifiable medical conditions — not age-related low testosterone alone.
A dual GIP and GLP-1 receptor agonist given by weekly injection, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management and obstructive sleep apnea with obesity (Zepbound).